PSIL AdvisorShares Psychedelics ETF

This is an actively managed fund that seeks long-term capital appreciation. under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities. The Fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange -listed equity securities, including common and preferred stock of U.S. and foreign mid, small and micro-capitalization companies, and in total return swaps intended to provide exposure to such companies.

$2.18  -0.02 (-0.91%)
As of 01/27/2023 16:00:00 EST     IEX book   CBOE book

---

ETF Information

---

Sponsor:     AdvisorShares
Category1:  Global Equity
Category2:  Single industry
Category3:  Healthcare
Morningstar category:  
Leverage factor:  1.00
Inception date:  09/16/2021
Current yield:  2.43%
Historical average yield:  0.89%
Market cap:  $7,238,000
Average volume:  24,678
Fees:     0.6800%
Investment style: Actively managed